817 related articles for article (PubMed ID: 35236664)
1. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
2. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.
Galmiche S; Luong Nguyen LB; Tartour E; de Lamballerie X; Wittkop L; Loubet P; Launay O
Clin Microbiol Infect; 2022 Feb; 28(2):163-177. PubMed ID: 35020589
[TBL] [Abstract][Full Text] [Related]
4. Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review.
Martinelli S; Pascucci D; Laurenti P
Front Public Health; 2023; 11():1108546. PubMed ID: 37033069
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis.
Yin J; Chen Y; Li Y; Wang C; Zhang X
Int J Infect Dis; 2022 Nov; 124():212-223. PubMed ID: 36241168
[TBL] [Abstract][Full Text] [Related]
6. Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.
Verleye A; Wijtvliet V; Abrams S; Hellemans R; Bougrea R; Massart A; Pipeleers L; Wissing KM; Ariën KK; De Winter BY; Van Damme P; Abramowicz D; Ledeganck KJ
Nephrol Dial Transplant; 2022 Jul; 37(8):1566-1575. PubMed ID: 35544087
[TBL] [Abstract][Full Text] [Related]
7. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of SARS-CoV-2 Vaccine Doses in Allogeneic Hemopoietic Stem Cell Recipients: A Systematic Review and Meta-Analysis.
Rubin M; Suelzer E; Ulschmid C; Thapa B; Szabo A; Bilal Abid M
Asian Pac J Cancer Prev; 2024 Feb; 25(2):393-399. PubMed ID: 38415523
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients.
Sakuraba A; Luna A; Micic D
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016444
[TBL] [Abstract][Full Text] [Related]
10. Humoral and Cellular Response of Transplant Recipients to a Third Dose of mRNA SARS-CoV-2 Vaccine: A Systematic Review and Meta-analysis.
Bailey AJM; Maganti HB; Cheng W; Shorr R; Arianne Buchan C; Allan DS
Transplantation; 2023 Jan; 107(1):204-215. PubMed ID: 36398334
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis.
Manothummetha K; Chuleerarux N; Sanguankeo A; Kates OS; Hirankarn N; Thongkam A; Dioverti-Prono MV; Torvorapanit P; Langsiri N; Worasilchai N; Moonla C; Plongla R; Garneau WM; Chindamporn A; Nissaisorakarn P; Thaniyavarn T; Nematollahi S; Permpalung N
JAMA Netw Open; 2022 Apr; 5(4):e226822. PubMed ID: 35412626
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis.
Mehrabi Nejad MM; Moosaie F; Dehghanbanadaki H; Haji Ghadery A; Shabani M; Tabary M; Aryannejad A; SeyedAlinaghi S; Rezaei N
Eur J Med Res; 2022 Feb; 27(1):23. PubMed ID: 35151362
[TBL] [Abstract][Full Text] [Related]
13. Seroconversion after SARS-CoV-2 vaccination is protective against severe COVID-19 disease in heart transplant recipients.
Kugler S; Vári DK; Veres DS; Király Á; Teszák T; Parázs N; Tarjányi Z; Drobni Z; Szakál-Tóth Z; Prinz G; Miheller P; Merkely B; Sax B
Immun Inflamm Dis; 2023 Nov; 11(11):e1086. PubMed ID: 38018598
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety.
Javadinia SA; Alizadeh K; Mojadadi MS; Nikbakht F; Dashti F; Joudi M; Harati H; Welsh JS; Farahmand SA; Attarian F
Front Endocrinol (Lausanne); 2022; 13():860238. PubMed ID: 35586627
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
[TBL] [Abstract][Full Text] [Related]
16. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
17. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.
Wang X; Haeussler K; Spellman A; Phillips LE; Ramiller A; Bausch-Jurken MT; Sharma P; Krivelyova A; Vats S; Van de Velde N
Front Immunol; 2023; 14():1204831. PubMed ID: 37771594
[TBL] [Abstract][Full Text] [Related]
19. Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies.
Petrelli F; Luciani A; Borgonovo K; Ghilardi M; Parati MC; Petrò D; Lonati V; Pesenti A; Cabiddu M
J Med Virol; 2022 Jun; 94(6):2837-2844. PubMed ID: 35118680
[TBL] [Abstract][Full Text] [Related]
20. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
